CommercialPrior AuthHigh impact
MPC August 2026
Blue Cross Blue Shield of Nebraska·NE · Wound Care, Podiatry, Plastic Surgery +3 more·Medical Policy
Effective date
Aug 1, 2026
We identified it
Jun 24, 2026
Summary
Blue Cross Blue Shield of Nebraska is implementing prior authorization requirements for amniotic membrane treatments, bioengineered skin substitutes, and sacroiliac joint pain treatments effective August 1, 2026. These policies establish strict medical necessity criteria including documentation of failed conservative treatment and specific approved product lists.
Action Required
By August 1, 2026: Billing team must update systems to require prior authorization for amniotic membrane treatments (policy I.200), bioengineered skin substitutes (policy I.202), and sacroiliac joint pain treatments (policy III.189) for BCBSNE patients. Create documentation checklists ensuring 4-week failed conservative treatment is documented, appropriate products are used from approved lists, and medical necessity criteria are met. Train providers on new requirements. Claims without prior authorization will be denied.